Sun, Apr 20, 2014, 8:24 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Cell Therapeutics, Inc. Message Board

  • nndung802000 nndung802000 Nov 21, 2012 2:37 PM Flag

    Novatis buy CTIC

    Do you think it is possible?

    Shares of Cell Therapeutics, Inc. (NASDAQ:CTIC) went straight up on Monday, on word of the licensing terms through which Novartis AG (NYSE:NVS) would be allowed to develop and commercialize Cell’s Pixuvri cancer drug, which was recently okayed by the European Commission. If Novartis elects to exercise its option on Pixuvri, it would owe Cell $7.5 million for a license fee, as much as $104 million in milestone payments, plus ongoing royalties.

    Now they just have to pay about 70M. market price of CTIC. A discount price plus 3 other products in phase 3.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.07+0.08(+2.68%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST